Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | UCART123 |
| Synonyms | |
| Therapy Description |
UCART123 are allogeneic T-cells that contain a chimeric antigen receptor (CAR) targeting CD123 (IL3RA) and an RQR8 depletion ligand, which potentially induce cytotoxicity in cells expressing CD123 (ASH Meeting, 2016, abstract nr 4039, PMID: 31360087). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| UCART123 | UCART-123|UCART 123|Universal CAR123-expressing T-lymphocytes | UCART123 are allogeneic T-cells that contain a chimeric antigen receptor (CAR) targeting CD123 (IL3RA) and an RQR8 depletion ligand, which potentially induce cytotoxicity in cells expressing CD123 (ASH Meeting, 2016, abstract nr 4039, PMID: 31360087). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03190278 | Phase I | UCART123 | Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT03203369 | Phase I | UCART123 | Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123) | Terminated | USA | 0 |